T he incidence and severity of skin and skin-structure infections have increased, and such infections impose a substantial burden on the health care system. [1] [2] [3] [4] Gram-positive bacteria, especially Staphylococcus aureus, are the most frequent cause of infection, accounting for almost 45% of pathogens. 5, 6 Antibiotic-resistant strains, especially methicillinresistant S. aureus (MRSA), complicate the effective management of skin infections. 7 Omadacycline is an aminomethylcycline antibiotic that can be administered once daily either orally or intravenously. It is derived from the tetracycline class and exhibits activity against gram-positive and gram-negative aerobes, anaerobes, and atypical bacteria. [8] [9] [10] [11] [12] In vitro and in vivo studies have shown that omadacycline circumvents the efflux and ribosomal protection mechanisms of tetracycline resistance and has activity against pathogens common in communityacquired infections, including MRSA. [10] [11] [12] In a completed phase 2 trial and a truncated phase 3 trial involving patients with complicated skin and skin-structure infections, omadacycline showed efficacy and an acceptable side-effect profile, similar to those observed with linezolid. 13, 14 This global, phase 3 trial, the Omadacycline in Acute Skin and Skin Structure Infections Study (OASIS-1), compared the efficacy and safety of once-daily omadacycline with those of twicedaily linezolid for the treatment of adults with acute bacterial skin and skin-structure infections.
Me thods

Trial Design and Oversight
OASIS-1 was a phase 3, double-blind, doubledummy, randomized, noninferiority trial conducted at 55 sites in the United States, Peru, South Africa, and multiple countries in Europe from June 2015 through May 2016 (Fig. S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org). This trial was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. The trial was approved by the institutional review board or ethics committee at each participating site. Each patient provided written informed consent. A data and safety monitoring committee that was independent of the trial sponsor provided ongoing monitoring of safety data.
Paratek Pharmaceuticals designed and conducted the trial and prepared the statistical analysis plan. Analyses were performed and data interpreted by Paratek Pharmaceuticals in conjunction with the authors. All the authors vouch for the integrity, completeness, and accuracy of the data and analyses and assume responsibility for the fidelity of the trial to the protocol and statistical analysis plan, which are available at NEJM.org. A medical writer who was supported by the sponsor assisted with preparation of a first draft of the manuscript.
Patient Population and Treatments
Adults 18 years of age or older with a qualifying skin infection (wound infection [e.g., from intravenous drug use or trauma], cellulitis or erysipelas, or major abscess [≤30% of randomly assigned patients]) were eligible. Qualifying infections had a contiguous surface area of at least 75 cm 2 and exhibited clear evidence of erythema, edema, or induration. The technique for lesion measurement was standardized across trial sites (see the Supplementary Appendix). Evidence of an inflammatory response was required. Patients were excluded if they used one or more doses of a potentially effective systemic antibacterial treatment or a topical antibacterial agent within 72 hours before the first dose of a trial drug or if they had infections that were expected to require more than 14 days of treatment or were associated with chronic (>3 months) skin lesions, ulcers, or wounds. Also excluded were patients with clinically significant liver or renal insufficiency and immunocompromised patients. Complete entry criteria are provided in the Supplementary Appendix.
Patients were randomly assigned, in a 1:1 ratio, to receive 7 to 14 days of omadacycline (100 mg given intravenously every 12 hours for two doses, then 100 mg given intravenously every 24 hours, with the option to transition to 300 mg given orally every 24 hours after ≥3 days) or linezolid (600 mg given intravenously every 12 hours, with the option to transition to 600 mg given orally every 12 hours after ≥3 days) (Fig. S1 in the Supplementary Appendix). Randomization was performed with an interactive response system according to a computer-generated schedule and used a block sequence with a size of six, with stratification according to type of infection and geographic region. The investigators and spon-T h e ne w e ngl a nd jou r na l o f m e dicine sor were unaware of the treatment assignments. Trial personnel who were unaware of the treatment assignments administered intravenous infusions and collected, reviewed, and entered data. Adherence to the oral regimen was monitored by trial site personnel through medication return and patient-completed diaries.
Analysis Populations, End Points, and Assessments
The intention-to-treat population included all randomly assigned patients. The safety population included randomly assigned patients who received any amount of a trial drug. The modified intention-to-treat population included patients in the intention-to-treat population who did not have a sole gram-negative causative pathogen at baseline. The clinical per-protocol population included patients in the modified intention-to-treat population who had a qualifying infection as per the criteria for trial entry, received a trial drug, did not receive any antibacterial agent not assigned within the trial that could confound interpretation of the results, and had an assessment of outcome during the protocol-defined window. The microbiologic modified intentionto-treat population included patients in the modified intention-to-treat population who had at least one gram-positive causative bacterial pathogen identified from a blood culture or from a culture of a microbiologic sample obtained from the primary site of acute bacterial skin or skinstructure infection at baseline. The microbiologic per-protocol population comprised patients who were included in both the microbiologic modified intention-to-treat population and the clinical per-protocol population.
As recommended by the Food and Drug Administration, the primary efficacy end point was early clinical response in the modified intentionto-treat population. Early clinical response was determined programatically and defined as survival with a reduction in lesion size of at least 20% at 48 to 72 hours after the first dose of a trial drug without rescue antibacterial therapy.
Key secondary efficacy end points were investigator-assessed clinical response at the posttreatment evaluation (7 to 14 days after the last dose of a trial drug) in the modified intentionto-treat population and the clinical per-protocol population (European Medicines Agency coprimary end points). Investigator-assessed clinical response was defined as survival with resolution or improvement in signs and symptoms of infection to the extent that further antibacterial therapy was unnecessary. The investigator also assessed clinical response at the end-of-treatment visit. Microbiologic response (defined in the Supplementary Appendix) was determined at the end-of-treatment visit and post-treatment evaluation visit in the microbiologic modified intention-to-treat population and the microbiologic per-protocol population. Missing data were classified as indeterminate responses and counted as treatment failures in analyses involving the modified intention-to-treat population and the microbiologic modified intention-to-treat population.
At the screening visit, samples were collected from the site of infection for Gram's stain and culture, and blood samples were collected within 24 hours before the first dose of a trial drug (see the Supplementary Appendix). A sponsor review team whose members were unaware of the treatment assignments and clinical outcome confirmed the pathogen status of isolates for which the pathogen status could not be determined programmatically according to the rules detailed in the statistical analysis plan. Safety was assessed on the basis of adverse events, vital signs, electrocardiograms (ECGs), and laboratory results. Adverse events that emerged after treatment initiation were those with an onset or worsening of severity that occurred at or any time after administration of the first dose of a trial drug through the final follow-up visit (30 to 37 days after the first dose of a trial drug).
Statistical Analysis
For early clinical response, assuming a rate of response of 82% in both treatment groups, a noninferiority margin of 10 percentage points, 90% power, and a one-sided alpha level of 0.025 and using the method of Farrington and Manning, we calculated that 632 patients were required. 15, 16 Under the assumption of an 85% rate of clinical response in both treatment groups, a noninferiority margin of 10 percentage points, a one-sided alpha level of 0.0125, and 632 patients, there was 89% power to show noninferiority for investigator-assessed clinical response at the posttreatment evaluation in the modified intention-to-treat population. Assuming a 90% rate of clinical response in both treatment groups, a noninferiority margin of 10 percentage points, and a one-sided alpha level of 0.0125, we calculated that 506 patients would provide 91% power to show noninferiority for investigator-assessed clinical response at the post-treatment evaluation in the clinical per-protocol population. Because patients with a sole gram-negative causative pathogen were to be excluded from the modified intention-to-treat population, the total sample size (intention-to-treat population) was increased to 650 (under the assumption that approximately 3% of patients in the intention-to-treat population would have a sole gram-negative pathogen).
A noninferiority margin of 10 percentage points was used for early clinical response on the basis of historical data from controlled trials comparing antibacterial drugs with non-antibacterial treatments.
17 These trials provide a conservative estimate of the treatment effect of 18 to 30 percentage points for absolute reduction in lesion area; thus, a noninferiority margin of 10 percentage points preserves more than 40% of the treatment effect. A noninferiority margin of 10 percentage points was used for investigatorassessed clinical response at the post-treatment evaluation. 18 A two-sided 95% confidence interval that was calculated with the Miettinen and Nurminen method 19 without stratification, for the difference in the rate of early clinical response in the modified intention-to-treat population or for the difference in the rate of investigatorassessed clinical response at the post-treatment evaluation in the modified intention-to-treat population and the clinical per-protocol population, was used to test for noninferiority of omadacycline as compared with linezolid. Noninferiority of omadacycline to linezolid was concluded if the lower limit of the 95% confidence interval for the between-group difference was greater than −10 percentage points.
Because early clinical response and investigatorassessed clinical response at the post-treatment evaluation were separate primary end points for the two regulatory agencies, control for multiple comparisons was not required. Differences between treatment groups in baseline variables were analyzed with the use of Fisher's exact test for categorical variables and the Wilcoxon ranksum test for continuous variables. No inferential analyses were conducted for other end points or analysis populations; thus, these analyses are considered to be descriptive.
R esult s
Trial Population
Of the 655 patients who underwent randomization (intention-to-treat population), 645 received at least one dose of a trial drug (safety population) (Fig. 1). A total of 28 patients in the intention-to-treat population had only gram-negative pathogens identified, leaving 627 patients in the modified intention-to-treat population. The demographic and clinical characteristics of the patients were well balanced between the treatment groups (Table 1, and Table S1 in the Supplementary Appendix). In the modified intentionto-treat population, the median lesion area at baseline was 299.5 cm 2 in the omadacycline group and 315.0 cm 2 in the linezolid group. At least one gram-positive pathogen that is known to cause acute bacterial skin and skin-structure infections was identified at baseline in 69.5% of the patients in the intention-to-treat population. In the microbiologic modified intention-to-treat population, MRSA was detected in 30.3% of the patients in the omadacycline group and 22.0% of those in the linezolid group (Table S2 in the  Supplementary Appendix) .
Overall, 71.9% of the patients in the microbiologic modified intention-to-treat population had a monomicrobial gram-positive infection, 12.7% had a polymicrobial gram-positive infection, and 15.4% had a polymicrobial mixed grampositive and gram-negative infection. In the modified intention-to-treat population, 11 patients (3.5%) in the omadacycline group and 9 (2.9%) in the linezolid group had bacteremia. A total of 70.5% of patients underwent a surgical procedure before the first dose of a trial drug, and 13.2% underwent a surgical procedure after the first dose; no significant differences were observed between the treatment groups. The mean duration of treatment was 4.4 days for intravenous therapy in each group, 5.5 days for oral therapy in the omadacycline group, and 5.4 days for oral therapy in the linezolid group. A transition from intravenous to oral therapy occurred in 88.5% of patients with omadacycline and 87.9% of patients with linezolid. The percentage In a post hoc analysis of the clinical per-protocol population, omadacycline was also noninferior to linezolid with respect to early clinical response (92.6% and 94.6%, respectively; difference, −1.9 percentage points; 95% CI, −6.1 to 2.1). Similarly, omadacycline was noninferior to linezolid with respect to investigator-assessed clinical response at the post-treatment evaluation in both the modified intention-to-treat population (rate of response, 86.1% and 83.6%; difference, 2.5 percentage points; 95% CI, −3.2 to 8.2) and the clinical per-protocol population (96.3% and 93.5%; difference, 2.8 percentage points; 95% CI, −1.0 to 6.9). Similar efficacy in the two treatment groups was also observed within subgroups based on infection type (Fig. 2) . Results for clinical response according to geographic region, lesion size, use of nonsteroidal antiinflammatory agents, and microbiologic response are provided in Table S4 in the Supplementary Appendix.
In both treatment groups, the median lesion size was reduced by approximately 50% on day 3. It was reduced by approximately 99% in both groups at the end of treatment.
The clinical efficacy of omadacycline was similar to that of linezolid in patients with infections caused by the most common pathogens in acute bacterial skin and skin-structure infec-
Figure 1 (facing page). Randomization and Populations Used for Analysis.
The intention-to-treat population included all randomly assigned patients. The safety population included randomly assigned patients who received any amount of a trial drug. The modified intention-to-treat population included patients in the intention-to-treat population who did not have a sole gram-negative causative pathogen at baseline. The clinical per-protocol population included patients in the modified intention-to-treat population who had a qualifying infection as per the criteria for trial entry, received a trial drug, did not receive any antibacterial agent not assigned within the trial that could confound interpretation of the results, and had an assessment of outcome during the protocoldefined window. The microbiologic modified intentionto-treat population included patients in the modified intention-to-treat population who had at least one grampositive causative bacterial pathogen identified from a blood culture or from a culture of a microbiologic sample obtained from the primary site of acute bacterial skin or skin-structure infection at baseline. The microbiologic per-protocol population comprised patients who were included in both the microbiologic modified intention-to-treat population and the clinical per-protocol population.
Characteristic
Omadacycline Linezolid * The safety population included randomly assigned patients who received any amount of a trial drug. The modified intention-to-treat population included randomly assigned patients who did not have a sole gram-negative causative pathogen at baseline. There were no significant differences (P<0.05) between treatment groups, as assessed by Fisher's exact test (for categorical variables) or the Wilcoxon rank-sum test (for continuous variables). Percentages may not total 100 because of rounding. † The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. Data were missing for one patient in the linezolid group. ‡ Wound infection was defined as an infection characterized by purulent drainage from a wound with surrounding erythema, edema, or induration extending at least 5 cm in the shortest distance from the peripheral margin. § Major abscess was defined as an infection characterized by a collection of pus within the dermis or deeper with surrounding erythema, edema, or induration extending at least 5 cm in the shortest distance from the peripheral margin. T h e ne w e ngl a nd jou r na l o f m e dicine tions (Table 2 ). Furthermore, rates of clinical response at the post-treatment evaluation were similar in the omadacycline and linezolid groups among patients with monomicrobial gram-positive infections (87.8% and 84.8%, respectively), polymicrobial gram-positive infections (74.2% and 81.5%), and polymicrobial mixed infections (80.5% and 75.9%). Clinical response at the posttreatment evaluation in the small subgroup of patients with bacteremia occurred in 82% of patients (9 of 11) who received omadacycline and 100% of patients (9 of 9) who received linezolid.
Safety population
Safety
The incidence of at least one adverse event that emerged after treatment initiation was 48.3% with omadacycline and 45.7% with linezolid ( 
no. of events/total no. (%)
10 (8 in the omadacycline group and 2 in the linezolid group) had a worsening of the underlying acute bacterial skin and skin-structure infections or had another infection and 3 (1 and 2 in the respective groups) used illicit drugs or had an overdose. In the omadacycline group, 1 patient died from an opiate overdose, and in the linezolid group, 1 patient died from cardiac arrest and 1 from cardiac failure. None of the serious adverse events (Table S6 and S7 in the Supplementary Appendix) or deaths was considered by the investigator to be related to the trial drug. Neither group had clinically relevant changes in vital signs, ECG findings, or laboratory measures.
Discussion
In this phase 3 trial, the efficacy of once-daily omadacycline, administered intravenously with the option to transition to oral administration, was noninferior to that of twice-daily linezolid for the treatment of acute bacterial skin and skin-structure infections. Efficacy was shown for both the primary end point (early clinical response), which was based on objective reduction in lesion size, and investigator assessment at the post-treatment evaluation, 7 to 14 days after the end of therapy.
17, 18 Efficacy results were consistent across trial populations and subpopulations, infection types, lesion sizes, and causative pathogens, including MRSA.
Among patients who were considered to have an early clinical response, 93.7% of the patients in the omadacycline group and 90.2% of those in the linezolid group were considered by the investigator to have a clinical response at the posttreatment evaluation. These results are consistent with those of other trials involving patients with acute bacterial skin and skin-structure infections and suggest an opportunity to study early clinical response in a real-world setting as a potential clinical tool for transition to oral therapy and earlier hospital discharge. 20, 21 Similar rates of adverse events were identified for omadacycline and linezolid. Nausea and vomiting were the most frequent gastrointestinal adverse events, a finding consistent with the known adverse-event profiles of tetracyclines and oxa- * The microbiologic modified intention-to-treat population included patients in the modified intention-to-treat population who had at least one gram-positive causative bacterial pathogen identified from a blood culture or from a culture of a microbiologic sample obtained from the primary site of acute bacterial skin or skin-structure infection at baseline. The pathogens listed are those detected in at least 10 patients in either treatment group. † Patients with both methicillin-susceptible and methicillin-resistant S. aureus isolates were counted only once in the overall count of S. aureus. ‡ This group includes Streptococcus anginosus, S. intermedius, and S. constellatus. § Of the three patients in the omadacycline group with S. pyogenes who were not considered by the investigator to have a clinical response, two had indeterminate (i.e., missing) results at the post-treatment evaluation. ¶ All E. faecalis isolates were vancomycin-susceptible.
Table 2. Investigator-Assessed Clinical Response at the Post-Treatment Evaluation According to Baseline Pathogen (Microbiologic Modified Intention-to-Treat Population).*
T h e ne w e ngl a nd jou r na l o f m e dicine zolidinones, but were not treatment limiting. 22, 23 Furthermore, Clostridium difficile infection was not observed in this trial, which is consistent with the potential lower risk of C. difficile infection associated with tetracyclines and oxazolidinones than with several other antibiotic classes. [24] [25] [26] [27] Depending on the type of infection present, empirical therapy for most community-acquired skin infections may necessitate agents active against S. aureus, including MRSA, and β-hemolytic streptococci. The growing proportion of resistant bacterial pathogens presents a challenge to treatment selection. 28, 29 Resistance to common antibiotics, including clindamycin, macrolides, tetracyclines, and trimethoprim-sulfamethoxazole, is a concern with β-hemolytic streptococci. 30, 31 S. aureus, inclusive of MRSA, is associated with high rates of resistance to most beta-lactams, fluoroquinolones, and clindamycin. 30, 31 Contemporary data are limited for the historical tetracyclines and trimethoprim-sulfamethoxazole; evaluations of trimethoprim-sulfamethoxazole in the past 5 years have been in uncomplicated infections with small lesion sizes or small abscesses. 28, [32] [33] [34] In addition, adverse events (e.g., tendon rupture associated with fluoroquinolones) 35 and the availability of only an intravenous formulation (e.g., glycopeptides), which has been shown to result in longer hospitalization than regimens that have intravenous and oral formulations, are prescribing considerations. [36] [37] [38] [39] Strengths of this trial were a trial design that involved enrollment of patients with common skin-infection types and large areas of skin involvement, high rates of identified bacterial pathogens, and consistent results observed across trial populations and subgroups. Limitations included the necessity of excluding patients with commonly treated infections acquired in the community (e.g., bite wounds and chronic skin infections, such as diabetic foot ulcers), in accordance with regulatory guidance. Another limitation of the trial is that per regulatory guidance, we have combined different types of acute bacterial skin and skin-structure infections, which may have different microbiologic causes and treatment guidelines. Although the trial was powered according to regulatory guidance to determine noninferiority of omadacycline, the trial was underpowered to determine noninferiority within the individual subtypes of infection. Because linezolid has minimal activity against gram-negative pathogens, this trial could not assess whether omadacycline is effective for infections caused by such pathogens (e.g., surgicalwound infections). Finally, the trial design, which mandated the minimum duration of overall and intravenous therapy, is limited in its capacity to provide information about appropriate timing of antibiotic discontinuation and intravenous-to- * Adverse events that emerged after treatment initiation were those with an onset or worsening of severity that occurred at or any time after administration of the first dose of a trial drug through the final follow-up visit (30 to 37 days after the first dose of a trial drug). Full lists of adverse events are provided in Tables S5 through S8 in the Supplementary Appendix. † The investigator, who was unaware of the treatment assignment, assessed whether the adverse event was related to treatment. ‡ In the omadacycline group, one patient died from an opiate overdose. In the linezolid group, one patient died from cardiac arrest and one from cardiac failure. § Shown are events that occurred in more than 2% of the patients in either trial group after treatment initiation. ¶ Events were reported as intravenous site infiltration, typically caused by difficulty in finding reliable venous access sites in patients with intravenous drug use. ‖ There were no reports of Clostridium difficile infection in either treatment group. oral switch that occur frequently at the time of discharge from the hospital. Additional real-world data on omadacycline treatment for acute bacterial skin and skin-structure infections would be helpful for addressing these questions.
In conclusion, once-daily omadacycline, administered intravenously with the option to transition to oral administration, was noninferior to twice-daily linezolid for the treatment of acute bacterial skin and skin-structure infections, with a similar safety and side-effect profile.
